S&P 500 rises as health care, tech gain to overshadow Fed independence concerns
Johanna Roberts, Executive Vice President, General Counsel & Secretary of Penumbra Inc (NYSE:PEN), recently executed a series of stock transactions, according to a recent SEC filing. On April 24, 2025, Roberts sold 600 shares of common stock at a weighted average price of $300.01 per share, amounting to a total sale value of $180,006. This transaction was part of a Rule 10b5-1 trading plan, allowing pre-planned sales.
In addition to the sale, Roberts also exercised stock options to acquire 600 shares at a price of $22.04 per share, totaling $13,224. Following these transactions, Roberts holds 66,159 shares of Penumbra’s common stock, with a portion subject to vesting conditions.
In other recent news, Penumbra reported strong financial results for the first quarter of 2025, with earnings per share (EPS) reaching $0.83 and revenue totaling $324.1 million. This marked a 16.3% increase in revenue and a notable 102.8% jump in EPS compared to the previous year, surpassing Wall Street estimates. The U.S. Thrombectomy business was a significant contributor, with sales rising by 25% to $187.9 million, despite weaker international sales. Penumbra has adjusted its revenue forecast to exclude $5 million from China due to macroeconomic factors but maintained its full-year guidance, projecting a 12-14% growth, equating to approximately $1.34 billion to $1.36 billion.
Analysts have responded positively to these results, with UBS, Stifel, and BTIG all raising their price targets for Penumbra shares, now set at $330, $318, and $320, respectively, while maintaining a Buy rating. UBS highlighted Penumbra’s ability to sustain double-digit growth in both sales and earnings, particularly in the U.S. market. Stifel noted the company’s improved gross margins and a raised growth forecast for U.S. Thrombectomy, while BTIG emphasized Penumbra’s strategic position in the market and potential for exceeding guidance estimates.
Penumbra’s strategic focus on innovation and market expansion is further underscored by its recent submission of a 510K for the THUNDERBOLT product, anticipated to launch in the second half of 2025. The company also benefits from having its manufacturing and a majority of raw material sourcing in the U.S., reducing tariff exposure. These developments collectively suggest a favorable outlook for Penumbra in the medical device sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.